Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 1, 2013, Pages 79-86

  Grohskopf, Lisa A ^a   Chillag, Kata L ^a   Gvetadze, Roman ^b   Liu, Albert Y ^c   Thompson, Melanie ^d   Mayer, Kenneth H ^e   Collins, Brandi M ^f   Pathak, Sonal R ^f   O'hara, Brandon ^f   Ackers, Marta L ^a   Rose, Charles E ^b   Grant, Robert M ^g   Paxton, Lynn A ^a   Buchbinder, Susan P ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^d AIDS Research Consortium of Atlanta   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NORTHROP GRUMMAN CORPORATION   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral agents; Clinical trial; HIV; Phase 2; Preexposure prophylaxis; PrEP; Prevention and control; Tenofovir

Indexed keywords

CREATININE; PLACEBO; TENOFOVIR DISOPROXIL;

ADULT; ARTICLE; BACKACHE; BONE DENSITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLATULENCE; FRACTURE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOPHOSPHATEMIA; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; SEXUAL BEHAVIOR; SIDE EFFECT; SOCIAL BEHAVIOR; THERAPY DELAY; UNITED STATES; UPPER ABDOMINAL PAIN;

ADENINE; ADOLESCENT; ANTI-HIV AGENTS; BOSTON; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GEORGIA; HIV INFECTIONS; HIV SERONEGATIVITY; HOMOSEXUALITY, MALE; HUMANS; HYPOPHOSPHATEMIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ORGANOPHOSPHONATES; SAN FRANCISCO; TREATMENT OUTCOME;

EID: 84883461037     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828ece33     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Thirty years of HIV - -2011. MMWR Morb Mortal Wkly Rep. 2011;60:689
2. Joint United Nations Programme on HIV/AIDS. Epidemic update. In: UNAIDS Report on the Global AIDS Epidemic, 2010. Geneva, Switzerland: UNAIDS; 2010:16-61
3. Centers for Disease Control and Prevention. HIV surveillance - United States, 1981-2008. MMWR Morb Mortal Wkly Rep. 2011; 60:65-68
4. Prejean J, Song R, Hernandez A, et al; for the HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009 PLoS One. 2011;6:e17502
5. Garcia-Lerma JG, Cong M, Mitchell J, et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2:1-8
6. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS One. 2010;5:1-11
7. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PloS Med. 2008;5:e28
8. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 2009;194:904-911
9. Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet ;380:325
10. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599
11. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; for the TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367: 423-434
12. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410
13. Family Health International. FHI Statement on the FEM-PrEP HIV Prevention Study. Available at: Http://fhi.org/en/AboutFHI/Media/Releases/FEM-PrEP- statement041811.htm. Accessed February 16, 2013
14. Microbicide Trials Network. MTN Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, aMajor HIV Prevention Study in Women. Available at: Http://www.mtnstopshiv.org/node/3619. Accessed February 16, 2013
15. Okwundu CI, Okoromah CAN. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals (review). Cochrane Database Syst Rev. 2009;1:1-23
16. Nelson M, Katlama C, Montaner J, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first four years. AIDS. 2007;21:1273-1281
17. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689-696
18. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis. 2002; 40:1331-1333
19. Coca S, Perazella M. Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324:342-344
20. Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282-283
21. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: Report of seven cases. J Acquir Immune Defic Syndr. 2004;35:269-273
22. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171-1177
23. Tosini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010;24:2375-2380
24. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr ;47:494-499
25. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials ;8:164-172
26. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688
27. Hardin JW, Hilbe JM. Generalized Estimating Equations. Boca Raton, FL: Chapman and Hall/CRC Press; 2003
28. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000
29. Kleinbaum DG. Survival Analysis: A Self-Learning Text. New York, NY: Springer-Verlag; 1996
30. Gilead Sciences. Viread Package Insert. Foster City, CA: Gilead Sciences; 2012
31. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21: 1074-1090
32. Centers for Disease Control and Prevention. Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-68
33. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: Implications for oral pre-and post-exposure prophylaxis. AIDS. 2007;21:1899-1907
34. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112re4
35. Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high risk behavior. AIDS. 2004;18:787-792
36. Underhill K, Operario D, Skeer M, et al. Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquir Immune Defic Syndr. 2010;55:8-13